Senti Biosciences Holdings, Inc. Common Stock (SNTI) Stock Price

SNTIStock

$0.39−77.02%52W

Market Cap$12.17M

P/E—

PEG Ratio—

Div yield—

Beta2.22

SNTI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-70.16%

Price vs S&P 500 (4W)-4.00%

VGM Score11.32

Book Value / Share (Quarterly)$0.08

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-82.75%

Cash Flow / Share (Quarterly)$-1.19

Price vs S&P 500 (YTD)-75.61%

Net Profit Margin (TTM)-49178.95%

EPS (TTM)$-1.92

10-Day Avg Trading Volume0.34M

EPS Excl Extra (TTM)$-1.92

Revenue Growth (5Y)-47.77%

EPS (Annual)$-2.73

ROI (Annual)-1099.27%

Net Profit Margin (5Y Avg)-57781.84%

Cash / Share (Quarterly)$0.29

ROA (Last FY)-119.94%

EBITD / Share (TTM)$-1.97

ROE (5Y Avg)-289.37%

Operating Margin (TTM)-61189.47%

Cash Flow / Share (Annual)$-1.41

P/B Ratio4.66x

P/B Ratio (Quarterly)9.86x

Net Income / Employee (Annual)$-1,575,300

EV / Revenue (TTM)79.59x

Net Interest Coverage (TTM)-30.43x

ROA (TTM)-97.86%

EPS Incl Extra (Annual)$-2.73

Current Ratio (Annual)1.67x

Quick Ratio (Quarterly)0.57x

3-Month Avg Trading Volume0.26M

52-Week Price Return-77.02%

Revenue / Employee (TTM)$1,000

P/S Ratio (Annual)543.62x

Asset Turnover (Annual)0.00x

52-Week High$2.88

Operating Margin (5Y Avg)-64708.33%

EPS Excl Extra (Annual)$-2.73

CapEx CAGR (5Y)-29.94%

26-Week Price Return-58.91%

Quick Ratio (Annual)1.31x

13-Week Price Return-61.59%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.04x

Enterprise Value$3.02M

Revenue / Share Growth (5Y)-62.20%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$600

Pretax Margin (Annual)-279263.64%

Cash / Share (Annual)$0.53

3-Month Return Std Dev118.29%

Net Income / Employee (TTM)$-1,321,700

ROE (Last FY)-1099.27%

EPS Basic Excl Extra (Annual)$-2.73

Receivables Turnover (TTM)0.25x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.92

Receivables Turnover (Annual)0.09x

ROI (TTM)-503.79%

P/S Ratio (TTM)314.73x

Pretax Margin (5Y Avg)-57838.39%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)-95.33%

Year-to-Date Return-63.65%

5-Day Price Return-12.11%

EPS Normalized (Annual)$-2.73

ROA (5Y Avg)-64.55%

Net Profit Margin (Annual)-279263.64%

Month-to-Date Return11.01%

EBITD / Share (Annual)$-2.94

Operating Margin (Annual)-312631.82%

ROI (5Y Avg)-289.29%

EPS Basic Excl Extra (TTM)$-1.92

P/B Ratio (Annual)4.89x

Pretax Margin (TTM)-49178.95%

Book Value / Share (Annual)$0.18

Price vs S&P 500 (13W)-64.38%

Beta2.22x

Revenue / Share (TTM)$0.00

ROE (TTM)-503.79%

52-Week Low$0.33

vGradeD

gGradeF

mGradeF

vgmGradeF

SNTI Earnings Surprise History

Q2 25-0.56est. -0.90

Q3 25-0.69est. -0.57

Q4 25-0.53est. -0.47

Q1 26-0.14est. -0.36

Q2 26-0.42est. -0.27

SNTI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.20

4.22

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
SNTISenti Biosciences Holdings, Inc. Common Stock	D	F	F	$0.39
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Senti Biosciences Holdings, Inc. Common Stock

Senti Biosciences is a clinical-stage biotech company developing CAR-NK cell therapies—engineered cancer treatments controlled by its proprietary gene circuit platform. Its approach targets cancer cells while preserving healthy tissue, aiming to reduce treatment side effects. Lead candidates include SENTI-202 for various cancers and SENTI-301A for hepatocellular carcinoma.